The blood sugar supplement category has grown significantly alongside consumer interest in metabolic health, continuous glucose monitoring, and functional nutrition. Berberine, chromium picolinate, cinnamon extract, alpha-lipoic acid, bitter melon — these ingredients have clinical evidence for effects on glucose metabolism. The compliance challenge is that their evidence base is precisely what makes their claims highest-risk.
What FDA Permits for Blood Sugar Claims
Under 21 CFR 101.93(f), supplements may make structure/function claims about supporting normal glucose metabolism and healthy blood sugar levels in healthy individuals. These are generally permissible:
"Supports healthy blood sugar levels already within the normal range"
"Promotes healthy glucose metabolism"
"Supports healthy insulin sensitivity within the normal range"
"Helps maintain healthy carbohydrate metabolism"
"Supports healthy metabolic function"
"Promotes healthy pancreatic function"
The phrase "already within the normal range" is essential. Without it, claims about blood sugar and insulin function imply management of elevated levels — which is treatment of a disease state.
Where Blood Sugar Claims Become Disease Claims
Prohibited disease claims:
"Lowers blood sugar" — implies treatment of elevated blood sugar (hyperglycemia), a disease state
"Improves insulin resistance" — insulin resistance is a defined metabolic condition
"Helps manage diabetes" — explicit disease management claim
"Reduces A1C" — A1C is a diabetes diagnostic and management biomarker
"For people with prediabetes" — targeting a disease population
"Helps control blood sugar spikes" — blood sugar spikes are associated with diabetes and metabolic disease
"Reduces post-meal glucose levels" — implies treatment of abnormal post-meal glucose (a diabetes marker)
"Natural alternative to Metformin" — directly references a diabetes drug; implies equivalent treatment
The "supports healthy blood sugar" qualifier matters
The FDA's standard for disease claims under 21 CFR 101.93(g) requires looking at the full context of the labeling. "Supports healthy blood sugar levels" appears permissible on its face. If the same label is marketed with imagery of glucose meters, diabetes awareness ribbons, or copy targeting people who "struggle with their blood sugar," the full context converts the claim into an implied disease claim for people with diabetes or prediabetes.
Berberine: The Highest-Profile Case
Berberine has been widely compared to metformin in clinical literature for its effects on blood glucose and insulin sensitivity. This comparison, which appears in peer-reviewed research, has led to supplement brands marketing berberine as a "natural metformin alternative."
That framing is a disease claim under multiple criteria of 21 CFR 101.93(g)(2):
It references a drug used to treat diabetes (21 CFR 101.93(g)(2)(iv)(B))
It implies substitution for a disease therapy (21 CFR 101.93(g)(2)(vi))
It implies equivalent treatment of a named disease
Berberine supplement claims must describe its role in supporting normal glucose metabolism — not its equivalence to a diabetes drug. The clinical evidence for berberine is interesting and real; the marketing framing that flows naturally from that evidence is almost uniformly disease-claim territory.
Chromium and the Authorized Claim
Chromium picolinate has an FDA-qualified health claim (not a full authorized health claim) related to insulin resistance. The claim states that chromium picolinate may reduce the risk of insulin resistance, but the evidence is not conclusive. This is a highly qualified claim with a required disclaimer — not a blanket permission to make blood sugar management claims for chromium.
Using the qualified health claim requires the exact approved language and the required disclaimer. Adapting it, strengthening it, or treating it as general permission for blood sugar claims is a misuse of the qualified health claim framework.
Metabolic Health Positioning
Some brands have moved toward "metabolic health" positioning as a way to communicate blood sugar benefits without disease claim language. This can be compliant if done carefully:
"Supports metabolic health" is a structure/function claim
"Supports healthy metabolic function" is permissible
"Supports metabolic health for people with metabolic syndrome" implies treatment of a disease
"Optimizes your metabolism" crosses into implied outcome claims without substantiation
Blood sugar claims require the clearest bright-line compliance review in supplement marketing
Truli's product scans flag blood sugar and glucose claim language against the 21 CFR 101.93(g) disease claim criteria — specifically flagging claims about lowering, managing, or controlling blood sugar that cross from structure/function support into disease treatment, and identifying marketing context that converts otherwise permissible claims into implied disease claims.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
